PRESS RELEASE: Thomson Reuters ONE Ad-hoc/Biofrontera AG: Ameluz® Cooperation Agreement for Slovenia with PHA FARMED Consultancy s.p.

Biofrontera AG / Misc. matters / Ad hoc: Biofrontera AG: Ameluz® Cooperation Agreement for Slovenia with PHA FARMED Consultancy s.p. . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Leverkusen, 22 February 2013 - Biofrontera Pharma GmbH, a fully-owned subsidiary of Biofrontera AG, has today signed an exclusive agreement with PHA Farmed s.p., Ljubljana, for the marketing of Ameluz(®) in Slovenia. In December 2011 Ameluz(®) received a centralized European approval as prescription medicinal product for the first-line treatment of mild and moderate actinic keratosis in the face and on the scalp.

To assure the efficient and successful penetration of the Slovenian market with Ameluz(®) PHA Farmed provides fully integrated expert solutions as strategic partnership at all stages of the pharmaceutical business process.

PHA Farmed will support Biofrontera in the marketing of Ameluz(®) in Slovenia, a market in which German or English labeling on tubes and packages is accepted upon application. Biofrontera will thus be able to sell Ameluz(®) without the need for separate manufacturing to a local wholesaler for further distribution. All activities and costs related to marketing and sales, local reimbursement and pricing negotiations, and local pharmacovigilance will be taken on by PHA Farmed. In return, PHA Farmed will receive 40% of the revenues that Biofrontera achieves in this Territory with Ameluz(®).

Ameluz(®) is used in the treatment of actinic keratosis, a superficial skin cancer, by photodynamic therapy (PDT). The treatment combines Ameluz(®) with a strong red light illumination, provided f.i. through Biofrontera's BF- RhodoLED(®) lamp, the marketing of which is also ruled by the agreement between the two companies.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen ISIN: DE0006046113 WKN: 604611

Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290 E-mail: a.zurmuehlen@biofrontera.com

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Biofrontera AG via Thomson Reuters ONE [HUG#1680388]

--- End of Message ---

Biofrontera AG Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;ISIN: DE0006046113; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Regulierter Markt in Frankfurter Wertpapierbörse, Regulierter Markt in Börse Düsseldorf;

http://www.biofrontera.com/ (END) Dow Jones Newswires

   February 22, 2013 06:32 ET (11:32 GMT)- - 06 32 AM EST 02-22-13